Pharmafile Logo
Pharmafocus logo
Advanced Search

biosimilars

Showing 15 posts of 87 posts found.

top_10_image

Top Ten most popular articles on Pharmafile.com this week

October 19, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit

Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with …

News
29496564944_a9faceb1c2_z

Trump signs trust-busting biosimilar bill into law

October 11, 2018
Business Services, Sales and Marketing FTC, Trump, biosimilars, generics, us politics

President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of …

News
shutterstock_235920349

Are biosimilars key to solving NHS access concerns?

October 1, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Pfizer, UK, biosimilars, celltrion, pharma

In light of continued austerity gripping the NHS, it was uplifting to hear in July that the health service had …

Feature
pharmafocus_october_2018

The October 2018 issue of Pharmafocus is available to read online now!

September 27, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Hurricane Florence, NHS, Pharmafocus, US, biosimilars, market access, mental health, pharma

The October issue of Pharmafocus is available to read in full online now!Hurricane Florence lashed across North America’s Southeast coast …

News
white-house-13863_960_720

Senate bill would save money and allow generics to reach market more quickly, according to CBO report

September 20, 2018
Business Services, Medical Communications, Sales and Marketing CBO, Senate, US, biosimilars, generics, law, politics

The Congressional Budget Office (CBO) has said in a report that a bipartisan bill awaiting a vote in the senate …

News
16193381408_003eb2fdc9_z1

Irish trade lobby warns EU amendments could threaten pharma industry in Ireland, critics contest

August 6, 2018
Sales and Marketing EU, IPHA, Ireland, biosimilars, generics, intellectual property, trade lobby

The Irish Pharmaceutical Healthcare Association (IPHA) has warned that changes to existing intellectual property legislation could threaten innovation and deter …

News
rowa_vmax

Biosimilars and generics saved NHS £324m last year

August 2, 2018
Medical Communications, Sales and Marketing Cancer, NHS, biosimilars, funding, generics

The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by …

News

Study finds Herceptin use can be halved

May 17, 2018
Medical Communications, Research and Development Herceptin, Roche, biosimilars, biotech, drugs, pharma, pharmaceutical

A team of researchers from the University of Cambridge and Warwick Clinical Trials have revealed that Roche’s Herceptin is just …

News
top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

News

Sandoz US woes continue with biosimilar rejection

May 3, 2018
Sales and Marketing Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

In Novartis’ recently released Q1 results, which largely beat analysts’ estimates, Sandoz was a black spot on its record – …

News
shutterstock_92671375

US court upholds ruling that J&J’s Remicade patent is invalid

January 24, 2018
Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Remicade, biosimilars, infliximab, patent, pharma

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis …

News
sandoz

Novartis enters biosimilar agreement with Biocon

January 19, 2018
Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …

News
2018

Seven pharma trends for 2018

December 22, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2018, M&A, MA, biosimilars, collaborations, digital pharma, emerging markets, patient centricity, pharma, pricing

Pharmafile.com looks ahead to signpost what we expect will be the key industry trends through the course of 2018.The value of …

Feature

What will Pfizer do with its second Remicade biosimilar?

December 14, 2017
Sales and Marketing Ixifi, Johnson & Johnson, Pfizer, Remicade, biosimilars, biotech, drugs, inflectra, pharma, pharmaceutical

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these …

News
sandoz

Sandoz psoriasis biosimilar tops reference product Humira in latest Phase 3 data

September 15, 2017
Medical Communications, Research and Development AbbVie, Humira, Novartis, Sandoz, adalimumab, biosimilar, biosimilars, pharma, pharmaceutical

Sandoz, the biologics and generics division of Novartis, has unveiled new Phase 3 data confirming the efficacy and safety profile …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023